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Tumor size smaller than 4 cm as an indication for surgical treatment of incidentaloma is still a subject of discussion. Our aim was the 
estimation of the incidence of malignancy and analysis of treatment outcomes in patients with incidentaloma smaller than 4 cm in 
comparison to bigger lesions. 132 patients who underwent laparoscopic adrenalectomy for nonsecreting tumors were divided into 
two groups: group 1 (55  pts., size< = 40 mm) and group 2 (77 pts., size > 40 mm). Operation parameters and histopathological results 
were analyzed. No differences in group characteristics, mean operation time, and estimated blood loss were noted. Complications 
in groups 1 and 2 occurred in 3.6% and 5.2% of patients, respectively (𝑃 = 0.67). Malignancy in groups 1 and 2 was present in 1 and 
6 patients, respectively (𝑃 = 0.13). Potentially malignant lesions were identified in 4 patients in group 1 and 4 patients in group 2 
(𝑃 = 0.39). The results do not allow for straightforward recommendations for surgical treatment of smaller adrenal tumors. The 
safety of laparoscopy and minimal, but impossible to omit, risk of malignancy support decisions for surgery. On the other hand, the 
risk of malignancy in smaller adrenal tumors is lower than surgical complications, which provides an important argument against 
surgery.
1. Introduction
Incidentalomas are a group of hormonally inactive adrenal
tumors incidentally found during imaging studies performed
in patients due to symptoms unrelated to adrenal tumors.
Patients diagnosed and treated for neoplastic disorders of
other organs are excluded as metastasis to the adrenal glands
should be suspected at first place in that group of patients [1].
The prevalence of incidentaloma grows with the patients’ age
[2]. A steady increase in this diagnosis can also be observed
over the last few decades. According to the latest data such
lesions can be found in 4–10% of patients [1, 3, 4].This greater
incidence of hormonally inactive tumors results at least
partially from the higher quality and precision of imaging
techniques available today compared to those at the end of
the previous century. Nowadays imaging is based on high res-
olution computed tomography (CT) or magnetic resonance
imaging (MRI) as opposed to ultrasound (US), which was
used for diagnosis in the past. However, it also seems impos-
sible to exclude the fact that there is a real increase in the
incidence of incidentaloma in the general population [1, 5].
Even though current guidelines clearly list the indications
for adrenalectomy (tumor size, abrupt growth found in
follow-up studies, or radiologic appearance suggesting a
malignant lesion), the final decision whether to operate or to
follow up belongs to the surgeon [6]. The greatest concern is
the potentially malignant character of an adrenal tumor.
Adrenal cortical carcinoma, which is quite rare, is, like other
even more rare malignancies, found mainly in large tumors
[3]. Despite this fact, evidence of possible malignancy in
smaller adrenal tumors also exists [2]. The poor prognosis
associated with this type of tumors can prompt amore radical
approach also in the case of smaller lesions [7–9]. Different
values of tumor size as indication for surgical treatment can
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2014, Article ID 658483, 5 pages
http://dx.doi.org/10.1155/2014/658483
2 International Journal of Endocrinology
Table 1: Characteristics of the study groups of patients.
Group 1 (tumor < 4 cm), 𝑛 = 55 Group 2 (tumor ≥ 4 cm), 𝑛 = 77 𝑃 value
Female/male 39 (71%)/16 (29%) 52 (68%)/25 (32%) 0.69
Left side/right side 29 (53%)/26 (47%) 40 (52%)/37 (48%) 0.93
Mean age 57 years (±11.4) (24–76) 52.9 years (±14.1) (19–81) 0.15
Average tumor size 3.13 cm (±0.57) (1.2–3.8) 5.63 cm (±2.2) (4–16) <0.001
be found in various sources in the literature. The size quoted
usually ranges from 3 to 5 cm, and one of themost commonly
used is 4 cm [6, 10, 11]. With an increase in the upper range
of tumor size the risk of missed potentially resectable malig-
nancy increases. On the other hand, an overconfident belief
in the safety of minimally invasive procedures may lead to an
unjustified broadening of the inclusion criteria for surgery in
the case of smaller tumors.This can expose a larger number of
patients to postoperative complications without obvious ben-
efits.
2. Aim
The aim of this study is the evaluation of the incidence of
malignant or potentially malignant lesions in patients with
hormonally inactive adrenal tumors smaller than 4 cm in
diameter in comparison to the group of patients with lesions
greater than 4 cm in diameter. The second aim was the
analysis of early treatment results in relation to the tumor size.
3. Materials and Methods
The study focused on the retrospective analysis of patients
who underwent laparoscopic lateral transperitoneal adrena-
lectomy between 2003 and 2013. The inclusion criterion was
the presence of an adrenal tumor incidentally discovered in
imaging studies (computed tomography, CT; magnetic res-
onance imaging, MRI; ultrasound, US). During diagnostic
workout hormonal activity and active malignant processes of
other origins were excluded. Patients with a previous history
of malignancies were excluded as well. The main indication
for adrenalectomy in case of hormonally inactive tumors was
size above 40mm. In case of smaller lesions the decision on
surgery was based on significant growth in follow-up CT/
MRI or a so-called malignant phenotype discovered in
imaging.
In the analyzed period 468 adrenalectomies were per-
formed at our center. In 319 patients the indication for the
surgical treatment was the presence of a hormonally active
adrenal tumor, in case of 17 patients, metastasis from another
source. The study group consisted of the 132 remaining
patients with hormonally inactive and incidentally discov-
ered tumors. Patients were divided into two groups, accord-
ing to tumor size. Group 1 included 55 patients (39 females
and 16 males) with a tumor not larger than 40mm in dia-
meter. Group 2 included 77 patients (52 females and 25
males) with a tumor larger than 40mm in diameter. Table 1
presents the characteristics of the study groups. Operation
time, conversion rate, perioperative complications, and
histopathological results were analyzed. Blood loss was mea-
sured by volume in the suction container. This method was
sufficiently accurate, as irrigation was never used in case of
laparoscopic adrenalectomy. During the evaluation of the
pathological results, the lesions were classified into one of 3
categories: benign, potentially malignant, and malignant.
Tumorswere classified as potentiallymalignant if they did not
present overt features of malignancy intraoperatively or
histologically; however, as we have known from the literature,
they occasionally show malignant behavior [12].
Chi-square, Student’s 𝑡-, and Pearson correlation tests
were used in statistical analysis. 𝑃 < 0.05 was considered
significant.
4. Results
The characteristics of the study groups are presented in
Table 1. There were no statistically significant differences
between groups in regard to the gender, age, or the side where
the tumor was located.
There were no conversions to open surgery in group 1
and in group 2 conversions were necessary in two cases (𝑃 =
0.34). Reasons for conversions included adhesions after pre-
vious surgeries in one patient and tumor capsule rupture in a
patient with an 8 cm tumor highly suspected to bemalignant.
Mean operation time in group 1 was 77min., while in group
2 81min. (𝑃 = 0.713; Figure 1).
Mean estimated blood loss in group 1 was 37mL and
81mL in group 2. No statistically significant difference was
shown between the groups (𝑃 = 0.136; Figure 2).
Complications occurred in two (3.6%) patients in group 1
(wound infection and pleural effusion, respectively; 1st and
2nd grade in the Clavien-Dindo classification). Complica-
tions in group 2 occurred in four (5.2%) patients. They
included diaphragm injury, inferior vena cava injury that was
sutured laparoscopically during the primary procedure (3rd
grade in the Clavien-Dindo classification), hematoma in the
removed adrenal tumor’s bed (2nd grade), and wound infec-
tion (1st grade in the Clavien-Dindo classification). The dif-
ference between the number of complications in the study
groups is not statistically significant (𝑃 = 0.67). None of the
patients required reoperation.Therewere no deaths in the 30-
day postoperative period.
During the histopathological analysis of the results in
group 1 only one malignant lesion was found (1.8%) and in
four patients (7.2%) lesions that were regarded potentially
malignant were found. Group 2 had six cases (7.8%) of malig-
nant lesions and in an additional four patients tumors that
were considered potentially malignant were found. Table 2
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Table 2: Histological types of removed lesions.
Histological type Group 1 Group 2 𝑃 value
Benign
Cortical adenoma
50 (91%)
42 (76.4%)
68 (88.3%)
43 (55.8%)
0.72
Adrenal cyst 3 (5.4%) 12 (15.6%)
Angiomyolipoma 2 (3.6%) 9 (11.7%)
Cavernous haemangioma 1 (1.8%) 0 (0%)
Schwannoma 1 (1.8%) 2 (2.6%)
Ganglioneuroma 1 (1.8%) 2 (2.6%)
Potentially malignant Pheochromocytoma 4 (7.2%) 2 (3.6%) 3 (3.9%) 3 (3.9%) 0.39
Oncocytic adrenal adenoma 2 (3.6%) 0 (0%)
Malignant Adrenal cortex cancer 1 (1.8%) 1 (1.8%) 6 (7.8%) 5 (6.5%) 0.13
Primary neuroectodermal tumor 0 (0%) 1 (1.3%)
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Figure 1: Mean operation time in studied groups.
presents the histological types of the removed adrenal
tumors.
5. Discussion
Until the mid-1990s adrenalectomies were performed in
highly specialized endocrinological surgery hospitals. The
procedure was considered difficult and risky, with high
morbidity and mortality rates. In 1992 Gagner was the first to
report laparoscopic adrenalectomy and this significantly
influenced the development of endocrine surgery [13, 14].
Even though the introduction of minimally invasive tech-
niques theoretically should not influence the indications for
the surgery, an appreciable increase in the number of
adrenalectomies in many centers can be observed. A low risk
of complications, shorter hospital stays, and more rapid
recovery contributed to high popularity of laparoscopic
adrenalectomy. Endocrinologists refer their patients more
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Figure 2: Mean estimated blood loss in studied groups.
willingly to centers where laparoscopic surgery is successfully
performed [15, 16]. There is now a general assumption that
minimally invasive techniques provide a relatively safe and
predictable way to treat adrenal tumors. There is, however, a
risk that this situation can prompt surgeons to operate on
patients that potentially could instead be safely followed up.
One of the greatest concerns here is the borderline tumor
size that constitutes an indication for surgery [17, 18]. The
upper limit of the size of tumors that can be removed bymin-
imally invasive technique has not been clearly established.
However, this problem is less controversial as there are many
reports on successful laparoscopic adrenalectomy for large
tumors [19–21]. The question concerning the lower limit of
tumor size that constitutes an indication for the operative
treatment seems to be more important. This criterion has
changed several times, ranging from 2 to 6 cm. The majority
of authors advocate surgery for tumors between 3 and 5 cm in
diameter. It seems that most surgeons, though certainly not
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all of them, accepted a lower limit of the tumor size of 4 cm
as an indication for the surgical treatment [3, 11].
The greatest concern in the case of hormonally inactive
adrenal tumors is the potential for malignancy, which can
occur even in relatively small tumors. It is well known that the
incidence of cancer is associated with the size of the tumor. In
lesions over 6 cm it can vary between 5% and 25% [7]. Yet, it is
strikingly lower in the case of tumors smaller than 4 cm (0.8–
2%) [13]. In our group, adrenal cortex cancerwas found in one
patient (1.8%) in group 1 and in five patients (6,5%) in group 2.
These data are relevant to the reports from the literature and
confirm the hypothesis that adrenal malignancy in case of
small incidentalomas is rare, but still possible. However, the
concern aboutmissedmalignancymay lead to a potential risk
of overtreatment, as the objective incidence of these lesions is
relatively low [3].
The extended indications for surgery in the case of small
tumors should include their characteristics in commonly
used imaging techniques. The sensitivity and specificity of
CT in case of typical adrenal adenoma are 71% and 98%,
respectively [22–24]. Unfortunately, even up to 30% of ade-
nomas do not present a typical image in CT and cannot be
differentiated from malignant lesions [8]. Similarly to CT,
MRI in up to 10–30%of cases cannot distinguish the character
of the adrenal tumor [8, 25]. The inability to reliably assess
up to 1/3 of all incidentalomas presenting the so-called
radiologically malignant phenotype is one of the most com-
mon factors influencing the decision about surgery. Other
imaging techniques, like scintigraphy or scintigraphy with
metaiodobenzylguanidine, are used rather in the case of hor-
monally active tumors, while PET CT may be of some value
in the case of suspected metastases in patients with a history
of malignancy [1]. These methods, however, are not routinely
used in the diagnostics of incidentalomas and have little
influence on the decision about surgery.
The outcome of the follow-up in patients with lesions that
were not operated on is another important issue. The review
of 21 studies by Kapoor et al. included 1690 patients with inci-
dentalomas smaller than 4 cm treated conservatively. It was
noticed that, in follow-up (1.5 to 7 years), progression in size
was present in 12.5% of patients, and a decrease in tumor size
was observed in 4.3% of cases. Additionally, hormonal activ-
ity appeared in 1.2% of patients. The overall risk of growth of
the adrenal tumors at surveillance in a 5-year period was esti-
mated to be 18–29% [1].The change in the size or character of
the tumor is a significant criterion indicating the need for
surgery. It can be assumed that every third patient with a
tumor smaller than 3 cmwill eventually require surgical treat-
ment in the future. Unfortunately, it is impossible to predict
in whom changes in tumor size or character will occur.
Another factor favoring the removal of adrenal tumors
smaller than 4 cm is the safety profile provided by minimally
invasive techniques. It is represented by a low complication
rate, short hospital stay, and an absence of adverse long-term
outcomes. In our group of patients the complication rate was
3.6% and 5.1% in groups 1 and 2, respectively. There were no
complications higher than grade 3 in the Clavien-Dindo clas-
sification. Conversions, similarly to complications, were not
related to the size of the adrenal tumor. Additionally, the
operation time andmean estimated blood loss were similar in
both groups. None of the patients required reoperation.
Therefore, we can assume that tumor size within the range
discussed in this paper does not affect the results of sur-
gical treatment. We may thus conclude that laparoscopic
adrenalectomy is safe regardless of tumor size, and during the
qualification process one should not be guided by tumor size.
All these factorsmay lead to an increase in the overall number
of adrenalectomies for reasons poorly supported by scientific
evidence.
6. Conclusions
This study does not provide unequivocal conclusions regard-
ing the indications for and safety of laparoscopic adrenalec-
tomy in tumors smaller than 4 cm.The safety of laparoscopic
surgery and the minimal, though impossible to omit, risk of
development of malignancy provide an argument for surgical
treatment. On the other hand, the fact that the risk of malig-
nancy in adrenal tumors smaller than 4 cm is lower (1.8%)
than the risk of complications related to laparoscopic adren-
alectomy (3.6%) provides an important counterargument
against surgery.
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